MilliporeSigma, Jenner Institute partner on COVID-19 vaccine

By The Science Advisory Board staff writers

April 14, 2020 -- MilliporeSigma and the Jenner Institute have announced that they are preparing for large-scale manufacturing of the COVID-19 vaccine candidate ChAdOx1 nCoV-19.

While the vaccine is undergoing clinical trials, MilliporeSigma has evaluated an existing manufacturing platform for use with the new vaccine candidate, including critical processing steps. The normal process development would take six months to a year, but in just two months MilliporeSigma and the Jenner team have repurposed a previous platform to use for COVID-19 manufacturing.

MilliporeSigma is partnering with the Jenner Institute in the institute
MilliporeSigma is partnering with the Jenner Institute in the institute's efforts to develop a safe and effective vaccine for COVID-19. Image courtesy of MilliporeSigma.

Both companies have made investments over the last two years into the development of rapid, scalable platforms following good manufacturing practices and utilizing disposable technologies for the Jenner Institute's adenovirus platform. The initial work was developed with a rabies vaccine candidate and subsequently validated with different adenovirus constructs with the goal of accelerating future vaccine development and manufacturing.

The partnership, established in 2018, has become part of the rapid response to COVID-19 from the scientific community by accelerating large-scale manufacturing -- a critical and often time-consuming part of vaccine development.

ReForm gets patents for therapeutic protein formulations
ReForm Biologics has received a U.S. patent for therapeutic protein formulations that reduce protein aggregation and stabilize proteins during storage.
MilliporeSigma awarded U.S. patent for new CRISPR technology
MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second...
MilliporeSigma launches Lanexo software at Pittcon 2020
MilliporeSigma launched its Lanexo software for lab inventory, safety, and compliance management at the Pittcon meeting in Chicago on March 3. The new...
MilliporeSigma to make Elypta liquid biopsy kits
MilliporeSigma has signed an agreement with Swedish molecular diagnostics company Elypta to be the contract manufacturer for Elypta's clinical diagnostic...
MilliporeSigma unveils BrightLab for research scientists
MilliporeSigma has introduced BrightLab, a cloud-based inventory management and instrument connectivity platform for research scientists.
ReForm Biologics, MilliporeSigma ink license agreement
ReForm Biologics and MilliporeSigma have signed a licensing agreement to develop and market excipients used for biotherapeutic applications. The agreement...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter